Abstract 626P
Background
Circulating tumor DNA (ctDNA) analysis with comprehensive panels is now integral to cancer genomic profiling, advancing precision medicine in clinical practice. Yet, the practicality of treatment post ctDNA testing remains uncertain. This study aims to estimate treatment application post ctDNA analysis and its clinical utility.
Methods
Over a 7-month period, from January to July 2023, we retrospectively evaluated 102 patients with solid tumors who underwent ctDNA using the next generation sequencing method at a university-affiliated tertiary care hospital in Korea. To determine the percentage of genome-driven targeted therapy applied subsequent to ctDNA test result, we employed previously reported FDA-approved companion diagnostic biomarkers and their corresponding drug lists. Cases in which FDA-approved targeted therapy was prescribed or cases in which drugs were changed due to drug resistance after ctDNA testing were assessed.
Results
Out of 102 cases evaluated, 81 cases (79.4%) displayed ctDNA sequencing results featuring actionable variants classified as Tier 1 or Tier II. Among the 73 FDA-approved drugs, 12 were administered at our hospital between January 1, 2023, and July 31, 2023. According to ctDNA results, 21 individuals (20.6% of the total cases) were either prescribed FDA-approved drugs or underwent drug changes. Among them, 15 patients (14.7%) were prescribed FDA-approved drugs, while 6 patients (5.9%) experienced alterations in their medication regimens. Of the 21 patients undergoing targeted therapy based on ctDNA test results, colorectal cancer (12/21, 57.1%) was the most prevalent, followed by NSCLC (4/21, 19.0%). Consistent with these cancer types, the most frequently administered drugs were pembrolizumab (8/21, 38.1%) and cetuximab (6/21, 28.6%).
Conclusions
While this study presents findings from an investigation at a tertiary-hospital in Korea, it underscores the significant prevalence of genome-targeted therapy adoption following ctDNA testing for solid tumors. A larger-scale study should be pursued to further validate these observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract